3-(4-methanesulfonylphenyl)-1-(4-methylsulfanylphenyl)prop-2-yn-1-one | 742699-86-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 3-(4-methanesulfonylphenyl)-1-(4-methylsulfanylphenyl)prop-2-yn-1-one
• 英文别名: 1,3-Diarylprop-2-yn-1-one, 27；1-(4-methylsulfanylphenyl)-3-(4-methylsulfonylphenyl)prop-2-yn-1-one
• CAS: 742699-86-1
• 化学式: C₁₇H₁₄O₃S₂
• 分子量: 330.428
• InChiKey: LYLNGAGMHRAPQN-UHFFFAOYSA-N

物化性质

• 沸点：
  545.0±60.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  84.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4-methanesulfonylphenyl)-1-(4-methylsulfanylphenyl)prop-2-yn-1-one 在 Oxone 作用下， 以 1,4-二氧六环 为溶剂， 以75%的产率得到1,3-Bis-(4-methanesulfonyl-phenyl)-propynone
  参考文献：
  名称：

  1,3-二芳基丙-2-yn-1-ones的合成及其与构效关系的研究：环氧合酶和脂氧合酶的双重抑制剂。

  摘要：

  设计，合成和评估了一组具有C-3 p-SO2Me COX-2药效基团的1,3-二芳基丙-2-yn-1-ones（13、17、23、26和27），作为潜在的双重抑制剂环氧合酶1/2（COX-1 / 2）和5 / 15-脂氧合酶（5 / 15-LOX）具有体内抗炎和镇痛作用。在这类化合物中，3-（4-甲磺酰基苯基）-1-（4-氟苯基）丙-2-炔-1-酮（13h）被确定为有效和选择性的COX-2抑制剂（COX-2 IC50 = 0.1 microM； SI = 300），效力比罗非昔布高5倍（COX-2 IC50 = 0.5 microM； SI> 200）。在大鼠角叉菜胶诱导的爪水肿测定中，口服30 mg / kg剂量后3 h，13h表现出中等的抗炎活性（炎症抑制26％）。相关的双重COX-1 / 2和5 / 15-LOX抑制剂3-（4-甲磺酰基苯基）-1-（4-氰基苯基）丙-2-炔-1-酮（13g，COX-1

  DOI：

  10.1021/jm0510474
• 作为产物：
  描述：

  1-乙炔-4-(甲基磺酰基)-苯 在 manganese(IV) oxide 、 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 、 丙酮 为溶剂， 反应 0.05h， 生成 3-(4-methanesulfonylphenyl)-1-(4-methylsulfanylphenyl)prop-2-yn-1-one
  参考文献：
  名称：

  Design, Synthesis, and Structure−Activity Relationship Studies of 3,4,6-Triphenylpyran-2-ones as Selective Cyclooxygenase-2 Inhibitors

  摘要：

  A group of regioisomeric 3,4,6-triphenylpyran-2-ones with a MeSO2 pharmacophore at the paraposition of either a C-3 phenyl or a C-4 phenyl substituent on the central six-membered pyran-2-one ring were prepared and evaluated in vitro for their abilities to inhibit the isozymes COX-1 and COX-2. Structure-activity relationship (SAR) data, acquired by substituent modification at the para-position of the C-6 phenyl ring attached to the central pyranone, showed that 6-(4-methoxyphenyl)-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-one (12e) was the most potent and selective COX-2 inhibitor (COX-2 IC50 = 0.02 muM; COX-1 IC50 > 100 muM) with a high COX-2 selectivity index (SI > 5000) relative to the reference drugs celecoxib (COX-2 IC50 = 0.07 muM; SI = 474) and rofecoxib (COX-2 IC50 = 0.50 muM; SI > 200). 6-(4-Methoxyphenyl)-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-one (12e) was a more potent oral antiinflammatory agent (ID50 = 5.6 mg/kg) than celecoxib (ID50 = 10.8 mg/kg) in a carrageenan-induced rat paw edema assay. In a 4% NaCl-induced abdominal constriction assay, a 5 mg/kg oral dose of 12e exhibited good analgesic activity at different time intervals producing 37.5 and 69% inhibition of writhing at 30 and 60 min, respectively. In contrast, the corresponding 6-(4-methoxyphenyl)-4-(4-methanesulfonylphenyl)-3-phenylpyran-2-one regiosiomer (12o) was a less potent and selective COX-2 inhibitor (COX-2 IC50 = 0.45 muM; SI = 70). A molecular modeling study for 12e indicated that the p-OMe substituent on the C-6 phenyl ring interacts with the COX-2 binding site amino acids Ile(345), Val(349), Leu(359), Leu(531), and Met(535) and that the OMe substituent may be responsible for proper orientation of the C-3 p-SO2Me-phenyl ring within the COX-2 secondary pocket (Gln(192), Arg(513), and Phe(518)). These results show that the COX-2 selectivity and potency of 3,4,6-triphenylpyranone regioisomers can be modulated by appropriate placement of the p-SO2Me pharmacophore on either the C-3 or C-4 phenyl moiety. In addition, electronic properties at the para-position of a C-6 phenyl substituent on the central pyranone ring govern COX-2 inhibitory potency and selectivity by controlling the orientation of the p-SO2Me pharmacophore within the COX-2 secondary pocket.

  DOI：

  10.1021/jm049939b

文献信息

• Design, Synthesis, and Structure−Activity Relationship Studies of 3,4,6-Triphenylpyran-2-ones as Selective Cyclooxygenase-2 Inhibitors
  作者：P. N. Praveen Rao、Md. Jashim Uddin、Edward E. Knaus

  DOI：10.1021/jm049939b

  日期：2004.7.1

  A group of regioisomeric 3,4,6-triphenylpyran-2-ones with a MeSO2 pharmacophore at the paraposition of either a C-3 phenyl or a C-4 phenyl substituent on the central six-membered pyran-2-one ring were prepared and evaluated in vitro for their abilities to inhibit the isozymes COX-1 and COX-2. Structure-activity relationship (SAR) data, acquired by substituent modification at the para-position of the C-6 phenyl ring attached to the central pyranone, showed that 6-(4-methoxyphenyl)-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-one (12e) was the most potent and selective COX-2 inhibitor (COX-2 IC50 = 0.02 muM; COX-1 IC50 > 100 muM) with a high COX-2 selectivity index (SI > 5000) relative to the reference drugs celecoxib (COX-2 IC50 = 0.07 muM; SI = 474) and rofecoxib (COX-2 IC50 = 0.50 muM; SI > 200). 6-(4-Methoxyphenyl)-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-one (12e) was a more potent oral antiinflammatory agent (ID50 = 5.6 mg/kg) than celecoxib (ID50 = 10.8 mg/kg) in a carrageenan-induced rat paw edema assay. In a 4% NaCl-induced abdominal constriction assay, a 5 mg/kg oral dose of 12e exhibited good analgesic activity at different time intervals producing 37.5 and 69% inhibition of writhing at 30 and 60 min, respectively. In contrast, the corresponding 6-(4-methoxyphenyl)-4-(4-methanesulfonylphenyl)-3-phenylpyran-2-one regiosiomer (12o) was a less potent and selective COX-2 inhibitor (COX-2 IC50 = 0.45 muM; SI = 70). A molecular modeling study for 12e indicated that the p-OMe substituent on the C-6 phenyl ring interacts with the COX-2 binding site amino acids Ile(345), Val(349), Leu(359), Leu(531), and Met(535) and that the OMe substituent may be responsible for proper orientation of the C-3 p-SO2Me-phenyl ring within the COX-2 secondary pocket (Gln(192), Arg(513), and Phe(518)). These results show that the COX-2 selectivity and potency of 3,4,6-triphenylpyranone regioisomers can be modulated by appropriate placement of the p-SO2Me pharmacophore on either the C-3 or C-4 phenyl moiety. In addition, electronic properties at the para-position of a C-6 phenyl substituent on the central pyranone ring govern COX-2 inhibitory potency and selectivity by controlling the orientation of the p-SO2Me pharmacophore within the COX-2 secondary pocket.
• Synthesis and Structure−Activity Relationship Studies of 1,3-Diarylprop-2-yn-1-ones:  Dual Inhibitors of Cyclooxygenases and Lipoxygenases
  作者：P. N. Praveen Rao、Qiao-Hong Chen、Edward E. Knaus

  DOI：10.1021/jm0510474

  日期：2006.3.1

  (COX-1/2) and 5/15-lipoxygenases (5/15-LOX) that exhibit vivo antiinflammatory and analgesic activities. Among this class of compounds, 3-(4-methanesulfonylphenyl)-1-(4-fluorophenyl)prop-2-yn-1-one (13h) was identified as a potent and selective inhibitor of COX-2 (COX-2 IC50 = 0.1 microM; SI = 300), being 5-fold more potent than rofecoxib (COX-2 IC50 = 0.5 microM; SI > 200). In a rat carrageenan-induced

  设计，合成和评估了一组具有C-3 p-SO2Me COX-2药效基团的1,3-二芳基丙-2-yn-1-ones（13、17、23、26和27），作为潜在的双重抑制剂环氧合酶1/2（COX-1 / 2）和5 / 15-脂氧合酶（5 / 15-LOX）具有体内抗炎和镇痛作用。在这类化合物中，3-（4-甲磺酰基苯基）-1-（4-氟苯基）丙-2-炔-1-酮（13h）被确定为有效和选择性的COX-2抑制剂（COX-2 IC50 = 0.1 microM； SI = 300），效力比罗非昔布高5倍（COX-2 IC50 = 0.5 microM； SI> 200）。在大鼠角叉菜胶诱导的爪水肿测定中，口服30 mg / kg剂量后3 h，13h表现出中等的抗炎活性（炎症抑制26％）。相关的双重COX-1 / 2和5 / 15-LOX抑制剂3-（4-甲磺酰基苯基）-1-（4-氰基苯基）丙-2-炔-1-酮（13g，COX-1